ERBB2 and breast cancer: Based on the positive results of monarchE trial (currently with a median follow-up of 42 months), abemaciclib have been approved by FDA, EMA and other medicine agencies for the adjuvant treatment of HR-positive and HER2-negative high-risk breast cancer.